ulcerative colitis uc type inflammatory bowel disease longterm condition results inflammation ulcers colon primary symptoms active disease abdominal pain diarrhea mixed blood weight loss fever anemia may also often symptoms come slowly range mild symptoms typically occur intermittently periods symptoms complications may include abnormal dilation colon megacolon inflammation eye joints liver colon cause uc theories involve immune system dysfunction genetics changes normal gut bacteria environmental rates tend higher developed world proposing result less exposure intestinal infections western diet removal appendix early age may diagnosis typically colonoscopy tissue dietary changes maintaining highcalorie diet lactosefree diet may improve several medications used treat symptoms bring maintain remission including aminosalicylates mesalazine sulfasalazine steroids immunosuppressants azathioprine biologic removal colon surgery may necessary disease severe respond treatment complications colon cancer removal colon rectum generally cures people ulcerative colitis usually present diarrhea mixed gradual onset persists extended period time weeks estimated people experience rectal bleeding varying severity experience watery loose stools increased stool frequency diarrhea people experience bowel additional symptoms may include fecal incontinence mucous rectal discharge nocturnal proctitis inflammation rectum people uc may experience urgency rectal tenesmus urgent desire evacuate bowels passage little tenesmus may misinterpreted constipation due urge defecate despite small volume stool passage bloody diarrhea abdominal pain may prominent features severe severity abdominal pain uc varies mild discomfort painful bowel movements abdominal high frequency bowel movements weight loss nausea fatigue fever also common disease flares chronic bleeding gi tract chronic inflammation iron deficiency often leads anemia affect quality clinical presentation ulcerative colitis depends extent disease individuals may severe disease upon initial onset substantial proportion people history uc without ongoing symptoms clinical remission objective evidence ongoing ulcerative colitis associated generalized inflammatory process affect many parts body sometimes associated extraintestinal symptoms initial signs contrast crohns disease affect areas gastrointestinal tract outside colon ulcerative colitis usually confined colon inflammation ulcerative colitis usually continuous typically involving rectum involvement extending proximally sigmoid colon ascending colon contrast inflammation crohns disease often patchy socalled skip lesions intermittent regions inflamed disease classified extent involvement depending far disease proctitis rectal inflammation left sided colitis inflammation extending descending colon extensive colitis inflammation proximal descending proctosigmoiditis describes inflammation rectum sigmoid colon pancolitis describes involvement entire colon extending rectum cecum usually associated crohns disease ileitis inflammation ileum also occurs uc individuals uc ileitis commonly occurs setting pancolitis occurring cases tends correlate activity colitis socalled backwash ileitis occur people pancolitis believed little clinical addition extent involvement uc also characterized severity severity disease defined symptoms objective markers inflammation endoscopic findings blood tests disease course impact disease daytoday patients categorized endoscopy fecal calprotectin levels indicators low risk future complications mild moderate uc include following parameters exhibiting less stools daily lack feverweight loss indicators include lack extraintestinal symptoms low levels inflammatory markers creactive protein crp erythrocyte sedimentation rate esr fecal calprotectin later age diagnosis mild disease correlates fewer four stools daily addition mild urgency rectal bleeding may occur mild disease lacks systemic signs toxicity eg fever chills weight changes exhibits normal levels serum inflammatory markers esr moderate severe disease correlates six stools daily frequent bloody stools moderate abdominal pain lowgrade fever anemia may esr crp usually mayo score incorporates combination clinical symptoms stool frequency amount rectal bleeding endoscopic findings physicians assessment severity often used clinically classify uc mild moderate acutesevere ulcerative colitis asuc severe form presents acutely severe symptoms fulminant type associated severe symptoms usually diarrhea rectal bleeding abdominal pain usually associated systemic symptoms including associated high mortality rate compared milder forms uc month mortality rate people fulminant uc may inflammation extending beyond mucosal layer causing impaired colonic motility leading toxic megacolon toxic megacolon represents medical emergency one often treated surgically serous membrane involved colonic perforation may ensue mortality rate people complications include hemorrhage venous thromboembolism secondary infections colon including c difficile cytomegalovirus ulcerative colitis may improve enter uc characterized immune dysregulation systemic inflammation may result symptoms complications outside colon commonly affected organs include eyes joints skin frequency extraintestinal manifestations reported uc may affect mouth individuals uc develop oral two common oral manifestations aphthous stomatitis angular aphthous stomatitis characterized ulcers mouth benign noncontagious often recurrent angular chelitis characterized redness corners mouth may include painful sores breaks rarely benign pustules may occur mouth pyostomatitis uc may affect eyes manifesting scleritis iritis conjunctivitis patients may asymptomatic experience redness burning itching eyes inflammation may occur interior portion eye leading uveitis uveitis cause blurred vision eye pain especially exposed light photophobia untreated uveitis lead permanent vision inflammation may also involve white part eye sclera overlying connective tissue episclera causing conditions called scleritis ulcerative colitis commonly associated uveitis uc may cause several joint manifestations including type rheumatologic disease known seronegative arthritis may affect large joints oligoarthritis vertebra ankylosing spondylitis several small joints hands feet peripheral often insertion site muscle attaches bone entheses becomes inflamed enthesitis inflammation may affect sacroiliac joint estimated around ibd patients suffer migratory arthritis synovitis inflammation synovial fluid surrounding joint occur months recur later times usually erode joint symptoms arthritis include joint pain swelling effusion often leads significant ankylosing spondylitis sacroilitis usually occur independent bowel disease activity ulcerative colitis may affect skin common type skin manifestation erythema nodosum presents uc patients develops raised tender red nodules usually appearing outer areas arms legs especially anterior tibial area nodules diameters measure approximately cm erythema nodosum due inflammation underlying subcutaneous tissue panniculitis biopsy display focal panniculitis although often unnecessary diagnosis contrast jointrelated manifestations erythema nodosum often occurs alongside intestinal disease thus treatment uc often lead resolution skin another skin condition associated uc pyoderma gangrenosum presents deep skin ulcerations pyoderma gangrenosum seen patients uc formation usually independent bowel pyoderma gangrenosum characterized painful lesions nodules become ulcers progressively grow ulcers often filled sterile puslike material cases pyoderma gangrenosum may require injection treatment may also involve inhibitors tumor necrosis factor tnf cytokine promotes cell associations determined skin ulcerative colitis include skin condition known hidradenitis suppurativa hs condition represents chronic process follicles become occluded leading recurring inflammation nodules abscesses even fistulas tunnels skin drain ulcerative colitis may affect circulatory endocrine system uc increases risk blood clots arteries painful swelling lower legs sign deep venous thrombosis difficulty breathing may result pulmonary embolism blood clots lungs risk blood clots threefold higher individuals risk venous thromboembolism high ulcerative colitis due hypercoagulability inflammation especially active extensive additional risk factors may include surgery hospitalization pregnancy use corticosteroids tofacitinib jak osteoporosis may occur related systemic inflammation prolonged steroid use treatment uc increases risk bone clubbing deformity ends fingers may amyloidosis may occur especially severe poorly controlled disease usually presents protein urine proteinuria nephritic ulcerative colitis significant association primary sclerosing cholangitis psc progressive inflammatory disorder small large bile ducts people primary sclerosing cholangitis ulcerative many people ulcerative colitis may progress develop primary sclerosing psc common men often begins years present asymptomatically exhibit symptoms itchiness pruritis fatigue symptoms include systemic signs fever night sweats symptoms often associated bacterial episodic version psc upon physical exam one may discern enlarged liver contours hepatomegaly enlarged spleen splenomegaly well areas excoriation yellow coloring skin jaundice may also present due excess bile byproduct buildup bilirubin biliary tract diagnosis lab results often reveal pattern indicative biliary disease cholestatic pattern often displayed markedly elevated alkaline phosphatase levels milder elevation liver enzyme levels xray results often show bile ducts thicker walls areas dilation cases primary sclerosing cholangitis occurs several years bowel symptoms ulcerative colitis psc parallel onset extent duration activity colonic inflammation ulcerative addition colectomy impact course primary sclerosing cholangitis individuals psc associated increased risk colorectal cancer cholangiocarcinoma bile duct psc progressive condition may result cirrhosis specific therapy proven affect long term course ulcerative colitis autoimmune disease characterized tcells infiltrating direct causes uc known factors genetics environment overactive immune system play uc associated comorbidities produce symptoms many areas body outside digestive system genetic component cause uc hypothesized based aggregation uc families variation prevalence different ethnicities genetic markers addition identical twin concordance rate whereas dizygotic twin concordance rate people ulcerative colitis family history inflammatory bowel addition people first degree relative uc fourfold increase risk developing twelve regions genome may linked uc including order discovery chromosomes none loci consistently shown fault suggesting disorder influenced multiple genes example chromosome band one region thought linked inflammatory bowel putative regions encode transporter proteins potential regions involve cell scaffolding proteins maguk family human leukocyte antigen associations may even work fact linkage chromosome may convincing consistent genetic multiple autoimmune disorders associated ulcerative colitis including celiac lupus rheumatoid episcleritis ulcerative colitis also associated acute intermittent many hypotheses raised environmental factors contributing pathogenesis ulcerative colitis including diet breastfeeding medications breastfeeding may protective effect development ulcerative one study isotretinoin found small increase rate colon exposed many dietary substances may encourage inflammation dietary factors hypothesized play role pathogenesis ulcerative colitis crohns disease however research show link diet development ulcerative colitis studies investigated association one study showed association refined sugar number people affected ulcerative high intake unsaturated fat vitamin may enhance risk developing ulcerative identified dietary factors may influence development andor relapse disease include meat protein alcoholic specifically sulfur investigated involved cause ulcerative colitis sulfur restricted diets investigated people uc animal models disease theory sulfur etiological factor related gut microbiota mucosal sulfide detoxification addition result classaction lawsuit community settlement dupont three epidemiologists conducted studies population surrounding chemical plant exposed pfoa levels greater general population studies concluded association pfoa exposure six health outcomes one ulcerative levels sulfatereducing bacteria tend higher persons ulcerative colitis could indicate higher levels hydrogen sulfide intestine alternative theory suggests symptoms disease may caused toxic effects hydrogen sulfide cells lining infection mycobacterium avium subspecies paratuberculosis proposed ultimate cause ulcerative colitis crohns increased amount colonic sulfatereducing bacteria observed people ulcerative colitis resulting higher concentrations toxic gas hydrogen sulfide human colonic mucosa maintained colonic epithelial barrier immune cells lamina propria see intestinal mucosal barrier nbutyrate shortchain fatty acid gets oxidized beta oxidation pathway carbon dioxide ketone bodies shown nbutyrate helps supply nutrients epithelial barrier studies proposed hydrogen sulfide plays role impairing betaoxidation pathway interrupting short chain acetylcoa dehydrogenase enzyme within pathway furthermore suggested protective benefit smoking ulcerative colitis due hydrogen cyanide cigarette smoke reacting hydrogen sulfide produce nontoxic isothiocyanate thereby inhibiting sulfides interrupting unrelated study suggested sulfur contained red meats alcohol may lead increased risk relapse people proposed mechanisms driving pathophysiology ulcerative colitis involve abnormal immune response normal gut microbiota involves abnormal activity antigen presenting cells apcs including dendritic cells macrophages normally dendritic cells macrophages patrol intestinal epithelium phagocytose engulf destroy pathogenic microorganisms present parts microorganism antigens tcells stimulate differentiation activation however ulcerative colitis aberrant activity dendritic cells macrophages results phagocytosing bacteria normal gut microbiome ingesting microbiome bacterium apcs release cytokine tnfα stimulates inflammatory signaling recruits inflammatory cells intestines leading inflammation characteristic ulcerative tnf inhibitors including infliximab adalimumab golimumab used inhibit step treatment ulcerative phagocytosing microbe apcs enter mesenteric lymph nodes present antigens naive tcells also releasing proinflammatory cytokines lead cell differentiation signaling blocked biologic ustekinumab blocked guselkumab mirikizumab risankizumab medications used treatment ulcerative mesenteric lymph node tcells enter intestinal lymphatic venule provides transport intestinal epithelium mediate inflammation characteristic ulcerative tcells exit lymphatic venule via adhesion protein mucosal vascular addressin cell adhesion molecule ulcerative colitis biologic treatment vedolizumab inhibits tcell migration lymphatic venules blocking binding medications ozanimod etrasimod inhibit receptor prevent tcell migration efferent lymphatic mature tcells exit efferent lymphatic venule travel intestinal mucosa cause inflammation tcell mediated inflammation thought driven jakstat intracellular tcell signaling pathway leading transcription translation release inflammatory cytokines tcell jakstat signaling inhibited medications tofacitinib filgotinib upadacitinib used treatment ulcerative initial diagnostic workup ulcerative colitis consists complete history physical examination assessment signs symptoms laboratory tests severe uc exhibit high erythrocyte sedimentation rate esr decreased albumin protein produced liver various changes electrolytes discussed previously uc patients often also display elevated alkaline phosphatase inflammation intestine may also cause higher levels fecal calprotectin specific testing may include although ulcerative colitis disease unknown causation inquiry made unusual factors believed trigger simple clinical colitis activity index created used assess severity best test diagnosis ulcerative colitis remains endoscopy examination internal surface bowel using flexible camera initially flexible sigmoidoscopy may completed establish physician may elect limit extent initial exam severe colitis encountered minimize risk perforation colon however complete colonoscopy entry terminal ileum performed rule crohns disease assess extent severity endoscopic findings ulcerative colitis include erythema redness mucosa friability mucosa superficial ulceration loss vascular appearance colon present ulcerations may confluent pseudopolyps may ulcerative colitis usually continuous rectum rectum almost universally involved perianal disease rare degree involvement endoscopically ranges proctitis rectal inflammation left sided colitis extending descending colon extensive colitis extending proximal descending biopsies mucosa taken endoscopy confirm diagnosis uc differentiate crohns disease managed differently clinically histologic findings ulcerative colitis includes distortion crypt architecture crypt abscesses inflammatory cells mucosa lymphocytes plasma cells unlike transmural inflammation seen crohns disease inflammation ulcerative colitis limited blood stool tests serve primarily assess disease severity level inflammation rule causes infectious colitis individuals suspected ulcerative colitis stool testing rule complete blood count may demonstrate anemia leukocytosis anemia may caused inflammation bleeding chronic blood loss may lead iron deficiency cause anemia particularly microcytic anemia small red blood cells evaluated serum ferritin iron total ironbinding capacity transferrin saturation anemia may due complication treatment azathioprine cause low blood sulfasalazine result folate deficiency thiopurine metabolites azathioprine folate level uc may cause high levels inflammation throughout body may quantified serum inflammatory markers crp esr however elevated inflammatory markers specific uc elevations commonly seen conditions including infection addition inflammatory markers uniformly elevated people ulcerative colitis twenty five percent individuals confirmed inflammation endoscopic evaluation normal crp serum albumin may also low related inflammation addition loss protein gi tract associated bleeding colitis low serum levels vitamin associated uc although significance finding specific antibody markers may elevated ulcerative colitis specifically perinuclear antineutrophil cytoplasmic antibodies panca found percent cases antibodies saccharomyces cerevisiae may present often positive crohns disease compared ulcerative colitis however due poor accuracy serolologic tests helpful diagnostic evaluation possible inflammatory bowel several stool tests may help quantify extent inflammation present colon rectum fecal calprotectin elevated inflammatory conditions affecting colon useful distinguishing irritable bowel syndrome noninflammatory flare inflammatory bowel fecal calprotectin sensitive specific diagnosis ulcerative fecal calprotectin low likelihood inflammatory bowel disease less lactoferrin additional nonspecific marker intestinal overall imaging tests xray ct scan may helpful assessing complications ulcerative colitis perforation toxic megacolon bowel ultrasound us costeffective welltolerated noninvasive readily available tool management patients inflammatory bowel disease ibd including uc clinical studies demonstrated bowel ultrasound accurate tool assessing disease activity people ulcerative imaging otherwise limited use diagnosing ulcerative magnetic resonance imaging mri necessary diagnose underlying abdominal xray often test choice may display nonspecific findings cases mild moderate ulcerative colitis circumstances severe uc radiographic findings may include thickening mucosa often termed thumbprinting indicates swelling due fluid displacement edema findings may include colonic dilation stool buildup evidencing similar xray mild ulcerative colitis double contrast barium enema often shows nonspecific findings conversely barium enema may display small buildups barium microulcerations severe uc characterized various polyps colonic shortening loss haustrae small bulging pouches colonand narrowing colon important note barium enema conducted patients exhibiting severe symptoms may slow stop stool passage colon causing ileus toxic methods imaging include computed tomography ct magnetic resonance imaging mri may depict colonic wall thickening decreased ability find early signs wall changes compared barium enema cases severe ulcerative colitis however often exhibit equivalent ability detect colonic doppler ultrasound last means imaging may used similar imaging methods mentioned earlier may show thickened bowel wall layers severe cases may show thickening bowel wall layers transmural several conditions may present similar manner ulcerative colitis excluded conditions include crohns disease infectious colitis nonsteroidal antiinflammatory drug enteropathy irritable bowel syndrome alternative causes colitis considered ischemic colitis inadequate blood flow colon radiation colitis prior exposure radiation therapy chemical colitis pseudomembranous colitis may occur due clostridioides difficile infection following administration antibiotics entamoeba histolytica protozoan parasite causes intestinal inflammation cases misdiagnosed uc poor outcomes occurring due use common disease mimics symptoms ulcerative colitis crohns disease inflammatory bowel diseases affect colon similar symptoms important differentiate diseases since courses treatments may differ cases however may possible tell difference case disease classified indeterminate crohns disease distinguished ulcerative colitis several ways characteristics indicate crohns include evidence disease around anus perianal disease includes anal fissures abscesses well fistulas abnormal connections various bodily infectious colitis another condition may present similar manner ulcerative colitis endoscopic findings also oftentimes similar one discern whether patient infectious colitis employing tissue cultures stool studies biopsy colon another beneficial test invasive forms colitis may present similarly include radiation diversion colitis radiation colitis occurs irradiation often affects rectum sigmoid colon similar ulcerative colitis upon histology radiation colitis may indicate eosinophilic infiltrates abnormal epithelial cells fibrosis diversion colitis hand occurs portions bowel loops removed histology condition often shows increased growth lymphoid tissue patients undergone transplantation graft versus host disease may also differential diagnosis response transplantation often causes prolonged diarrhea colon affected typical symptoms also include rash involvement upper gastrointestinal tract may lead difficulty swallowing ulceration upon histology graft versus host disease may present crypt cell necrosis breakdown products within crypts standard treatment ulcerative colitis depends extent involvement disease severity goal induce remission initially medications followed administration maintenance medications prevent relapse concept induction remission maintenance remission important medications used induce maintain remission somewhat overlap treatments different physicians first direct treatment inducing remission involves relief symptoms mucosal healing colons lining longerterm treatment maintain remission prevent acute stages disease low fiber diet may ulcerative colitis treated number medications including drugs sulfasalazine mesalazine corticosteroids prednisone also used due immunosuppressive shortterm healing properties risks outweigh benefits used longterm treatment immunosuppressive medications azathioprine biological agents infliximab adalimumab given people achieve remission corticosteroids infliximab ustekinumab vedolizumab recommended moderate severe formulation budesonide approved us food drug administration fda treatment active ulcerative colitis january tofacitinib approved treatment moderately severely active ulcerative colitis united states first oral medication indicated long term use evidence methotrexate show benefit producing remission people ulcerative cyclosporine effective severe tacrolimus also shown etrasimod velsipity approved medical use united states october sulfasalazine major agent therapy mild moderate ulcerative colitis years shown acid mesalazinemesalamine therapeutically active component many drugs developed aim delivering active compound large intestine maintain therapeutic efficacy reduction side effects associated sulfapyridine moiety sulfasalazine oral drugs particularly effective inducing maintaining remission mild moderate ulcerative rectal suppository foam liquid enema formulations used colitis affecting rectum sigmoid descending colon shown effective especially combined oral biologic treatments tnf inhibitors infliximab adalimumab golimumab commonly used treat people uc longer responding corticosteroids tofacitinib vedolizumab also produce good clinical remission response rates biologics may used early treatment step approach treatments failed induce remission step approach strategy unlike aminosalicylates biologics cause serious side effects increased risk developing extraintestinal heart failure weakening immune system resulting decreased ability immune system clear infections reactivation latent infections tuberculosis reason people treatments closely monitored often tested hepatitis tuberculosis etrasimod oncedaily oral sphingosine receptor modulator selectively activates receptor subtypes detectable activity development treatment immunemediated diseases including ulcerative colitis shown randomized trials effective well tolerated induction maintenance therapy patients moderately severely active ulcerative unlike crohns disease ulcerative colitis lesser chance affecting smokers select individuals history previous tobacco use resuming low dose smoking may improve signs symptoms active ulcerative recommended due overwhelmingly negative health effects studies using transdermal nicotine patch shown clinical histological one doubleblind placebocontrolled study conducted united kingdom people uc used nicotine patch conjunction standard treatment showed complete resolution symptoms another randomized doubleblind placebocontrolled singlecenter clinical trial conducted united states showed people used patch showed significant improvement versus given however nicotine therapy generally recommended due side effects inconsistent gradual loss blood gastrointestinal tract well chronic inflammation often leads anemia professional guidelines suggest routinely monitoring anemia blood tests repeated every three months active disease annually quiescent adequate disease control usually improves anemia chronic disease iron deficiency anemia treated iron supplements form treatment administered depends severity anemia guidelines followed advise parenteral iron used first people respond quickly associated fewer gastrointestinal side effects associated compliance others require oral iron used first people eventually respond many tolerate side many patients affected ulcerative colitis need immunosuppressant therapies may associated higher risk contracting opportunistic infectious many potentially harmful diseases hepatitis b influenza chickenpox herpes zoster virus pneumococcal pneumonia human papilloma virus prevented vaccines drug used treatment ibd classified according degree immunosuppression induced patient several guidelines suggest investigating patients vaccination status starting treatment performing vaccinations vaccine preventable diseases compared rest population patients affected ibd known higher risk contracting vaccinepreventable patients treated janus kinase inhibitor showed higher risk nevertheless despite increased risk infections vaccination rates ibd patients known suboptimal may also lower vaccination rates general unlike crohns disease gastrointestinal aspects ulcerative colitis generally cured surgical removal large intestine though extraintestinal symptoms may persist procedure necessary event exsanguinating hemorrhage frank perforation documented strongly suspected carcinoma surgery also indicated people severe colitis toxic megacolon people symptoms disabling respond drugs may wish consider whether surgery would improve quality removal entire large intestine known proctocolectomy results permanent ileostomy stoma created pulling terminal ileum abdomen intestinal contents emptied removable ostomy bag secured around stoma using another surgical option ulcerative colitis affecting large bowel called ileal pouchanal anastomosis ipaa two threestep procedure threestep procedure first surgery subtotal colectomy large bowel removed rectum remains situ temporary ileostomy made second step proctectomy formation ileal pouch commonly known jpouch involves removing large majority remaining rectal stump creating new rectum fashioning end small intestine pouch attaching anus procedure new type ileostomy created known loop ileostomy allow anastomoses heal final surgery takedown procedure ileostomy reversed longer need ostomy bag done two steps proctocolectomy removing colon rectum performed alongside pouch formation loop ileostomy final step takedown surgery threestep procedure time taken step vary typically six twelvemonth interval recommended first two steps minimum two three months required formation pouch ileostomy ileal pouch procedure removes need ostomy bag restore normal bowel function months following final operation patients typically experience bowel movements day time number decreases many patients reporting foursix bowel movements one year postop many patients success procedure number known complications pouchitis inflammation ileal pouch resulting symptoms similar ulcerative colitis relatively common pouchitis acute remitting chronic however treatment using antibiotics steroids biologics highly effective complications include fistulas abscesses pouch failure depending severity condition pouch revision surgery may need performed cased pouch may need defunctioned removed ileostomy risk cancer arising ileal pouch anal anastomosis however annual surveillance pouchoscopy may considered individuals risk factors dysplasia history dysplasia colorectal cancer history psc refractory pouchitis severely inflamed atrophic pouch number randomized clinical trials probiotics demonstrated potential helpful treatment ulcerative colitis specific types probiotics escherichia coli nissle shown induce remission people cochrane review controlled trials using various probiotics found lowcertainty evidence probiotic supplements may increase probability clinical people receiving probiotics likely experience disease remission likely report improvement symptoms compared receiving placebo clear difference minor serious adverse although clear evidence greater remission probiotic supplements compared acid treatment monotherapy likelihood remission higher probiotics used combination acid unclear whether probiotics help prevent future relapse people stable disease activity either monotherapy combination fecal microbiota transplant involves infusion human probiotics fecal enemas ulcerative colitis typically requires prolonged bacteriotherapy treatment clostridium difficile infection successful possibly due time needed heal ulcerated epithelium response ulcerative colitis potentially favorable one study reporting people experiencing complete studies found benefit using fecal microbiota variety alternative medicine therapies used ulcerative colitis inconsistent results curcumin turmeric therapy conjunction taking medications mesalamine sulfasalazine may effective safe maintaining remission people quiescent ulcerative effect curcumin therapy alone quiescent ulcerative colitis treatments using cannabis cannabis oil uncertain far studies determined effectiveness many interventions considered manage abdominal pain people ulcerative colitis including fodmaps diet relaxation training yoga kefir diet stellate ganglion block treatment unclear whether safe effective improving pain reducing anxiety diet play role symptoms patients ulcerative avoided foods patients spicy foods dairy products alcohol fruits vegetables carbonated beverages foods mainly avoided remission prevent relapse cases especially flares period dietary restrictions patients severe lead compromised nutritional state patients tend eliminate gluten spontaneously despite definite diagnosis coeliac disease believe gluten exacerbate gastrointestinal many studies found patients ibd reported higher frequency depressive anxiety disorders general population studies confirm women ibd likely men develop affective disorders show may depression disorder anxiety poor prognostic factors include age years upon diagnosis extensive colitis severe colitis endoscopy prior hospitalization elevated crp low serum people ulcerative colitis usually intermittent course periods disease inactivity alternating flares disease people proctitis leftsided colitis usually benign course progress proximally disease sustained remission absence therapy subset people experience course disease progress rapidly cases usually failure respond medication surgery often performed within first years disease people extensive disease less likely sustain remission rate remission independent severity several risk factors associated eventual need colectomy including prior hospitalization uc extensive colitis need systemic steroids young age diagnosis low serum albumin elevated inflammatory markers crp esr severe inflammation seen surgical removal large intestine necessary risk colorectal cancer significantly increased people ulcerative colitis ten years involvement beyond splenic flexure people backwash ileitis might increased risk colorectal people proctitis usually increased recommended people screening colonoscopies random biopsies look dysplasia eight years disease activity one two year people ulcerative colitis perhaps slightly increased overall risk death compared background however distribution causesofdeath differs general specific risk factors may predict worse outcomes higher risk mortality people ulcerative colitis including c difficile cytomegalovirus infection due together crohns disease million people affected year newly occurs per people per individuals disease common north america europe often begins people aged years among males females appear affected equal also become common since together ulcerative colitis crohns disease affect million people united appropriate treatment risk death appears general first description ulcerative colitis occurred around together crohns disease million people affected year ulcerative colitis newly occurs per people incidence total per individuals disease worldwide total people died due inflammatory bowel disease uc crohns peak onset years second peak onset occurring decade ulcerative colitis equally common among men appropriate treatment risk death appears similar general uc become common since geographic distribution uc crohns disease similar highest number new cases year uc found canada new zealand united disease common north america europe general higher rates seen northern locations compared southern locations united uc common western europe compared eastern worldwide prevalence uc varies per together ulcerative colitis crohns disease affect million people united crohns disease rates uc greater among ashkenazi jews decreases progressively persons jewish descent nonjewish caucasians africans hispanics appendectomy prior age current tobacco protective development however former tobacco use associated higher risk developing number new cases uc united states per per number people affected united states per canada number new cases per year per population new cases number people affected estimated per united kingdom per people newly develop condition year number people affected per approximately people united kingdom diagnosed term ulcerative colitis first used samuel wilks term entered general medical vocabulary afterwards william halewhite publishing report various cases ulcerative ulcerative colitis first subtype ibd helminthic therapy using whipworm trichuris suis shown randomized control trial iowa show benefit people ulcerative therapy tests hygiene hypothesis argues absence helminths colons people developed world may lead inflammation helminthic therapy fecal microbiota transplant induce characteristic white cell response diseased areas unexpected given ulcerative colitis thought involve alicaforsen first generation antisense oligodeoxynucleotide designed bind specifically human messenger rna watsoncrick base pair interactions order subdue expression propagates inflammatory response promoting extravasation activation leukocytes white blood cells inflamed increased expression observed within inflamed intestinal mucosa ulcerative colitis patients production correlated disease suggests potential therapeutic target treatment ulcerative gram positive bacteria present lumen could associated extending time relapse ulcerative series drugs development looks disrupt inflammation process selectively targeting ion channel inflammation signaling cascade known preclinical study rats mice inhibition disrupted production cytokines tnfα decreased colon inflammation effectively neutrophil extracellular resulting degradation extracellular reported colon mucosa ulcerative colitis patients clinical remission indicating involvement innate immune system fexofenadine antihistamine drug used treatment allergies shown promise combination therapy opportunely low gastrointestinal absorption high absorbed drug gastrointestinal secretion fexofenadine results higher concentration site inflammation thus drug may locally decrease histamine secretion involved gastrointestinal mast cells alleviate evidence etrolizumab effective ulcerative colitis phase trials underway etrolizumab humanized monoclonal antibody targets subunit integrins etrolizumab decreases lymphocytes trafficking similar vedolizumab another integrin antagonist type leukocyte apheresis known granulocyte monocyte adsorptive apheresis still requires largescale trials determine whether results small trials tentatively httpsenwikipediaorgwikiulcerativecolitis